Published in:
16-02-2024 | Pancreatic Cancer | ASO Author Reflections
ASO Author Reflections: A Novel Combination Index of Sialyl-Lewis Antigen-Related Tumor Markers Enhances Predictive Significance in Patients with a Modest Radiological Response to Neoadjuvant Treatment for Pancreatic Cancer
Authors:
Satoru Miyahara, MD, Hidenori Takahashi, MD, PhD, Hirofumi Akita, MD, PhD, Kazuki Sasaki, MD, PhD, Yosuke Mukai, MD, PhD, Yoshifumi Iwagami, MD, PhD, Shinichiro Hasegawa, MD, PhD, Daisaku Yamada, MD, PhD, Yoshito Tomimaru, MD, PhD, Takehiro Noda, MD, PhD, Hiroshi Wada, MD, PhD, Shogo Kobayashi, MD, PhD, Yuichiro Doki, MD, PhD, Hidetoshi Eguchi, MD, PhD
Published in:
Annals of Surgical Oncology
|
Issue 5/2024
Login to get access
Excerpt
Appropriate reevaluation after neoadjuvant treatment (NAT) is important for optimal treatment selection of pancreatic cancer (PC).
1 However, determining the operative eligibility of patients with a modest radiological response remains controversial. Biological factors have recently been emphasized in treatment strategies for PC. While CA19-9 is regarded as the main factor in clinical settings, recent studies also have investigated the significance of DUPAN-II as a Sialyl-Lewis antigen-related tumor marker.
2 Nevertheless, for patients with a modest radiological response, it remains unclear whether tumor markers, such as CA19-9 alone, DUPAN-II alone, and their combined evaluation during NAT, provides useful information. …
